Addex Therapeutics’ Post

The conviction that #serendipity can be, if not systematized, at least harnessed for augmented scientific discovery, has fueled my (obviously nonlinear) professional trajectory. As we saw with Fleming's "accidental" discovery of penicillin, the #AHA moment does not happen in a vacuum: the mind needs to be ready for the discovery (or "pasteurized" for chance to favor you). While researching other examples of serendipitous drug discovery, I came across an article about systematizing serendipity for cardiovascular drug discovery. It does not fully deliver on its promise, but I can't resist sharing that it is published in AHA journals. In case you are wondering, AHA is the American Heart Association. https://lnkd.in/gWhy2fUS

Join us tomorrow at 12pm EST for our ISOP-sponsored webinar! Hear from Michelle Przedborski, PhD, Principal Scientist - Modeling at Applied BioMath, and Saheli Sarkar, PhD, Principal Scientist - Biology at Applied BioMath, as they discuss how we developed a QSP model to mechanistically link the drug exposure profile to the pharmacodynamic effects for Atacicept and ALPN-303 for the treatment of autoimmune disease. Register for the webinar at: https://lnkd.in/eYkBdxNc #qsp #mathematicalmodeling #pharmacodynamic #autoimmunedisease

Recent study published in Nature Communications on the structural basis of CCR6 modulation by allosteric antagonists. The research reveals detailed insights into how small molecule antagonists, like OXM1 and OXM2, interact with CCR6 to disrupt its activation, offering new perspectives on targeting this receptor for chronic inflammatory diseases. The findings highlight the versatility of GPCR antagonism, providing valuable knowledge that could advance drug discovery efforts focused on CCR6. Exciting developments in the field of structural biology and drug design! #StructuralBiology #DrugDiscovery #GPCR #InflammationResearch https://lnkd.in/g5Xaqj3R

Have you registered for our ISOP-sponsored webinar on Thursday, March 21st, at 12pm EST? Hear from Michelle Przedborski, PhD, Principal Scientist - Modeling at Applied BioMath, and Saheli Sarkar, PhD, Principal Scientist - Biology at Applied BioMath, as they discuss how we developed a QSP model to mechanistically link the drug exposure profile to the pharmacodynamic effects for Atacicept and ALPN-303 for the treatment of autoimmune disease. Register for the webinar at: https://lnkd.in/eYkBdxNc #qsp #mathematicalmodeling #pharmacodynamic #autoimmunedisease

Did you register already? Link below

Exciting news! This Sunday marks the start of the 20th Annual Meeting of the Oligonucleotide Therapeutics Society in Montreal, Canada, and several members of the HAYA team will be attending.   Join us to discover how HAYA Therapeutics aims to transform patient care with programmable Regulatory Genome-guided therapeutics, and learn about the progress in our lead program, HTX-001—an antisense oligonucleotide targeting lncRNA WISPER, a master regulator of fibrosis in the heart. 🧬🫀   Be sure to stop by our posters to learn more about our innovative approach:   ➡️     Poster 174 | Building a Specialized Development Candidate Selection Process for Antisense Oligonucleotides Targeting IncRNAs ➡️    Poster 134 | WISPER from the Heart: Targeting a Cardiac Myofibroblast-specific LncRNA to Treat Cardiac 🗓 Tuesday, October 8, 15:45 - 18:45h EDT   Meet our team: James Karras, VP Translation María Marcuello, Ph.D R&D Lead HTX-001 Program Joaquim Cruz Corella, PhD, Computational Biologist For more information: https://lnkd.in/gXsgtqD5 #RNATherapeutics #OTS #ots24 #oligomeeting #HAYA #RegulatoryGenome #targetinglncRNAs

AnaBios is accepting abstracts for the 4th Annual AnaBios Translational Research Grant. The award of $15,000 in high-quality human tissue samples will help the winning academic #researcher advance his/her #translationalresearch project. To learn more details about the grant, including how to submit an abstract, visit our website. #drugdiscovery #heartresearch #painresearch #toxicology

We're accepting abstracts for the 4th Annual AnaBios Translational Research Grant. The award of $15,000 in high-quality human tissue samples will help the winning academic #researcher advance his/her translational research project. To learn more details about the grant, including how to submit an abstract, visit our website. #drugdiscovery #heartresearch #painresearch #toxicology #translationalresearch

Speakers at #CVCT concluded that randomised trials are not always feasible, and evidence from basic science, proof-of-concept and real-world registries or observational studies should be tapped to help advance drug development. Read our paper : https://lnkd.in/e4bmMZPt Harriette G. C. Van Spall, Reza Mohebi, Arnaud Bastien, Karsten Strauss, Ph.D, Steffen Thirstrup, James Min, MD, Bernard Gersh, Barry Greenberg, Faiez Zannad #clinicaltrials #clinicalresearch

The 4th Annual AnaBios Translational Research Grant is now open for abstract submissions. The winning scientist will receive $15,000 in tissue samples to propel their translational research project forward. Explore more about the grant and submission guidelines on our website. #TranslationalResearch #DrugDiscovery #HeartResearch #PainResearch #Toxicology